Significance of Increasing Levels of Minimal Residual Disease in Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Complete Cytogenetic Response [Hematologic Malignancies]

Posted by rob on July 29, 2009 under Uncategorized | Comments are off for this article

Conclusion
Most patients with increases in QPCR remain in CGCR. Patients who lose a MMR or never achieve a MMR, and have more than 1 log increase of QPCR, should be monitored more closely, and may be evaluated for mutations of BCR-ABL kinase domain and considered for investigational therapeutic interventions. (Source: Journal of Clinical Oncology)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed – updated hourly from thousands of authoritative health and news sources.

Tags:

Predictors of Primary Imatinib Resistance in Chronic Myelogenous Leukemia Are Distinct From Those in Secondary Imatinib Resistance [Hematologic Malignancies]

Posted by rob on under Uncategorized | Comments are off for this article

Conclusion
Gene expression profiling of CML at diagnosis for PTGS1 may be useful in predicting imatinib response and in selecting alternate therapy. (Source: Journal of Clinical Oncology)

Tags:

home top